Skeletal endocrinology: where evolutionary advantage meets disease

Abstract

The regulation of whole-body homeostasis by the skeleton is mediated by its capacity to secrete endocrine signaling molecules. Although bone-derived hormones confer several adaptive benefits, their physiological functions also involve trade-offs, thus eventually contributing to disease. In this manuscript, we discuss the origins and functions of two of the best-studied skeletal mediators, fibroblast growth factor 23 and osteocalcin, in an evolutionary context. Moreover, we provide a theoretical framework seeking to explain the broad involvement of these two hormones in amniote physiology as well as their potential to fuel the development and progression of diseases. Vice versa, we outline which perturbations might be amenable to manipulation of these systems and discuss limitations and ongoing challenges in skeletal endocrine research. Finally, we summarize unresolved questions and potential future studies in this thriving field.

References

[1] Wagner DO, Aspenberg P. Where did bone come from? Acta Orthop., 2011, 82: 393-398

[2] Briggs DE. The Cambrian explosion. Curr. Biol., 2015, 25: R864-R868

[3] Sipos, W. et al. Supporting apparatus of vertebrates: skeleton and bones. In Comparative Medicine: Anatomy and Physiology (ed Jensen-Jarolim, E.) 35–44 (Springer, 2014).

[4] Kawasaki K et al. Genetic basis for the evolution of vertebrate mineralized tissue. Proc. Natl Acad. Sci. USA, 2004, 101: 11356-11361

[5] Kuro-O M, Moe OW. FGF23-αKlotho as a paradigm for a kidney-bone network. Bone, 2017, 100: 4-18

[6] Ruben JA, Bennett AA. The evolution of bone. Evolution, 1987, 41: 1187-1197

[7] Pavlov E et al. Inorganic polyphosphate and energy metabolism in mammalian cells. J. Biol. Chem., 2010, 285: 9420-9428

[8] Ruben JA, Bennett AF. Intense exercise, bone structure and blood calcium levels in vertebrates. Nature, 1981, 291: 411-413

[9] Kukida M et al. AT2 receptor stimulation inhibits phosphate-induced vascular calcification. Kidney Int, 2019, 95: 138-148

[10] Kotas ME, Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell, 2015, 160: 816-827

[11] Han X et al. Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)₂ D in macrophages. FEBS Lett., 2016, 590: 53-67

[12] Wongdee K et al. Intestinal mucosal changes and upregulated calcium transporter and FGF-23 expression during lactation: contribution of lactogenic hormone prolactin. Arch. Biochem. Biophys., 2016, 590: 109-117

[13] Spichtig D et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int., 2014, 85: 1340-1350

[14] Leifheit-Nestler M et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol. Dial. Transpl., 2016, 31: 1088-1099

[15] Egli-Spichtig D, Zhang MYH, Perwad F. Fibroblast growth factor 23 expression is increased in multiple organs in mice with folic acid-induced acute kidney injury. Front. Physiol., 2018, 9: 1494

[16] Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat. Rev. Nephrol., 2020, 16: 7-19

[17] Bhattacharyya N et al. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol. Metab., 2012, 23: 610-618

[18] Hu MC et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev. Physiol., 2013, 75: 503-533

[19] David V et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int, 2016, 89: 135-146

[20] Zhang B et al. Up-regulation of FGF23 release by aldosterone. Biochem. Biophys. Res. Commun., 2016, 470: 384-390

[21] Ito N et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol. Cell Endocrinol., 2015, 399: 208-218

[22] Shimada T et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Min. Res., 2004, 19: 429-435

[23] Benet-Pagès A et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone, 2004, 35: 455-462

[24] Farrow EG et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc. Natl Acad. Sci. USA, 2011, 108: E1146-E1155

[25] Musgrove J, Wolf M. Regulation and effects of FGF23 in chronic kidney disease. Annu. Rev. Physiol., 2020, 82: 365-390

[26] Goetz R et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc. Natl Acad. Sci. USA, 2010, 107: 407-412

[27] Goetz R et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell Biol., 2007, 27: 3417-3428

[28] Singh S et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int, 2016, 90: 985-996

[29] Kuro-o M. A potential link between phosphate and aging-lessons from Klotho-deficient mice. Mech. Ageing Dev., 2010, 131: 270-275

[30] Kuro-o M et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature, 1997, 390: 45-51

[31] Patel S et al. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed. Pharmacother., 2017, 94: 317-325

[32] Andrukhova O et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol. Med, 2014, 6: 744-759

[33] Persson PB. Physiological regulation of renal blood flow and glomerular filtration rate by the endothelium and smooth muscle. Blood Purif., 1997, 15: 219-227

[34] Pathare G et al. Elevated FGF23 levels in mice lacking the thiazide-sensitive NaCl cotransporter (NCC). Sci. Rep., 2018, 8

[35] Xiao, Z. et al. FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model. JCI Insight 4, e132820 (2019).

[36] Agoro R et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J., 2018, 32: 3752-3764

[37] Braekkan SK et al. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica, 2010, 95: 270-275

[38] Walker RF et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern. Med., 2020, 180: 190-197

[39] Griesshammer M et al. Thromboembolic events in polycythemia vera. Ann. Hematol., 2019, 98: 1071-1082

[40] Smith-Jackson K et al. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J. Clin. Investig., 2019, 129: 1061-1075

[41] Isakova T et al. Longitudinal evolution of narkers of mineral metabolism in patients with CKD: the chronic renal Insufficiency cohort (CRIC) study. Am. J. Kidney Dis., 2020, 75: 235-244

[42] Greene EL et al. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Investig., 1996, 98: 1063-1068

[43] Isakova T et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA, 2011, 305: 2432-2439

[44] Helal I et al. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat. Rev. Nephrol., 2012, 8: 293-300

[45] Zhang Y et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials. Drugs, 2020, 80: 797-811

[46] Wanner, C. h., Inzucchi, S. E. & Zinman, B. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 1801–1802 (2016).

[47] Wanner C et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation, 2018, 137: 119-129

[48] Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr. Biol., 2012, 22: R733-R740

[49] Jaacks LM et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol., 2019, 7: 231-240

[50] Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet, 2015, 386: 801-812

[51] Faul C et al. FGF23 induces left ventricular hypertrophy. J. Clin. Investig., 2011, 121: 4393-4408

[52] Akhabue E. Fibroblast growth factor-23, heart failure risk, and renin-angiotensin-aldosterone-system blockade in hypertension: the multi-ethnic study of atherosclerosis. Am. J. Hypertens., 2019, 328: 18-25

[53] Metra M, Teerlink JR. Heart failure. Lancet, 2017, 390: 1981-1995

[54] Akhabue E et al. FGF23 (fibroblast growth factor-23) and incident hypertension in young and middle-aged adults: the CARDIA study. Hypertension, 2018, 72: 70-76

[55] Drew DA et al. Fibroblast growth factor 23 and blood pressure in older adults: the health, aging, and body composition study. Hypertension, 2020, 76: 236-243

[56] Calvo MS et al. Assessing the health impact of phosphorus in the food supply: issues and considerations. Adv. Nutr., 2014, 5: 104-113

[57] Ferrari SL et al. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab., 2005, 90: 1519-1524

[58] Imel EA et al. Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone, 2016, 86: 98-105

[59] Imel EA et al. Oral Iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophosphatemic rickets. J. Bone Min. Res, 2020, 35: 231-238

[60] Rousseau AF et al. Fibroblast growth factor 23 in acute burn patients: novel insights from an intact-form assay. Burns, 2016, 42: 1082-1087

[61] Courbebaisse M et al. Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease. Haematologica, 2017, 102: e33-e35

[62] Schaefer B. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br. J. Clin. Pharmacol., 2021, 87: 2256-2273

[63] Wolf M et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA, 2020, 323: 432-443

[64] Zoch ML et al. New insights into the biology of osteocalcin. Bone, 2016, 82: 42-49

[65] Ducy P et al. Increased bone formation in osteocalcin-deficient mice. Nature, 1996, 382: 448-452

[66] Lambert LJ et al. Increased trabecular bone and improved biomechanics in an osteocalcin-null rat model created by CRISPR/Cas9 technology. Dis. Model Mech., 2016, 9: 1169-1179

[67] Murshed M et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J. Cell Biol., 2004, 165: 625-630

[68] Bronckers AL et al. Studies of osteocalcin function in dentin formation in rodent teeth. Eur. J. Oral. Sci., 1998, 106: 795-807

[69] van de Loo PG et al. The effect of Gla-containing proteins on the precipitation of insoluble salts. Biochem. Biophys. Res. Commun., 1987, 142: 113-119

[70] Price PA et al. Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc. Natl Acad. Sci. USA, 1982, 79: 7734-7738

[71] Oury F et al. Endocrine regulation of male fertility by the skeleton. Cell, 2011, 144: 796-809

[72] Oury F et al. Maternal and offspring pools of osteocalcin influence brain development and functions. Cell, 2013, 155: 228-241

[73] Guedes JAC et al. Osteocalcin improves insulin resistance and inflammation in obese mice: participation of white adipose tissue and bone. Bone, 2018, 115: 68-82

[74] Berger JM. Mediation of the acute stress response by the skeleton. Cell Metab., 2019, 30: 890-902.e8

[75] Lacombe J et al. Measurement of bioactive osteocalcin in humans using a novel immunoassay reveals association with glucose metabolism and á-cell function. Am. J. Physiol. Endocrinol. Metab., 2020, 318: E381-E391

[76] Chowdhury S et al. Muscle derived interleukin-6 increases exercise capacity bysignaling in osteoblasts. J. Clin. Investig., 2020, 160: 2888-2902

[77] Ferron M et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl Acad. Sci. USA, 2008, 105: 5266-5270

[78] Ferron M et al. GGCX and VKORC1 inhibit osteocalcin endocrine functions. J. Cell Biol., 2015, 208: 761-776

[79] Lacombe J, Ferron M. Gamma-carboxylation regulates osteocalcin function. Oncotarget, 2015, 6: 19924-19925

[80] Khrimian L et al. Gpr158 mediates osteocalcin’s regulation of cognition. J. Exp. Med., 2017, 214: 2859-2873

[81] Wellendorph P, Bräuner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene, 2004, 335: 37-46

[82] Wellendorph P et al. Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol. Pharm., 2005, 67: 589-597

[83] Pi M et al. GPRC6A: Jack of all metabolism (or master of none). Mol. Metab., 2017, 6: 185-193

[84] Jacobsen SE et al. Delineation of the GPRC6A receptor signaling pathways using a mammalian cell line stably expressing the receptor. J. Pharm. Exp. Ther., 2013, 347: 298-309

[85] Wang, A. et al. An evolutionary perspective on immunometabolism. Science 363 eaar3932 (2019).

[86] Stearns, S. C. The Evolution of Life Histories, 249 (Oxford Univ. Press, 1992).

[87] Kandemir N et al. Bone parameters in anorexia nervosa and athletic amenorrhea: comparison of two hypothalamic amenorrhea states. J. Clin. Endocrinol. Metab., 2018, 103: 2392-2402

[88] Hackney, A. C. & Aggon, E. Chronic low testosterone levels in endurance trained men: the exercise-hypogonadal male condition. J. Biochem. Physiol. 1, 103 (2018).

[89] Muehlenbein MP, Bribiescas RG. Testosterone-mediated immune functions and male life histories. Am. J. Hum. Biol., 2005, 17: 527-558

[90] Wang A et al. Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation. Cell, 2016, 166: 1512-1525.e12

[91] Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharm. Sci., 2013, 34: 518-530

[92] Charmandari E et al. Endocrinology of the stress response. Annu Rev. Physiol., 2005, 67: 259-284

[93] Whirledge S, Cidlowski JA. Glucocorticoids, stress, and fertility. Minerva Endocrinol., 2010, 35: 109-125

[94] Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol. Rev., 2018, 98: 2133-2223

[95] Nandi A et al. The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia. Endocrinology, 2010, 151: 1863-1871

[96] Hondares E et al. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab., 2010, 11: 206-212

[97] Potthoff MJ et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl Acad. Sci. USA, 2009, 106: 10853-10858

[98] Kharitonenkov A et al. FGF-21 as a novel metabolic regulator. J. Clin. Investig., 2005, 115: 1627-1635

[99] Owen BM et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med., 2013, 19: 1153-1156

[100] Lewis JE et al. Going back to the biology of FGF21: new insights. Trends Endocrinol. Metab., 2019, 30: 491-504

[101] Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev., 2018, 281: 8-27

[102] Morelli A et al. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol. Cell Endocrinol., 2014, 382: 107-119

[103] Ebrahimi F et al. IL-1 antagonism in men with metabolic syndrome and low testosterone: a randomized clinical trial. J. Clin. Endocrinol. Metab., 2018, 103: 3466-3476

[104] Lennartsson AK et al. Sex steroid levels temporarily increase in response to acute psychosocial stress in healthy men and women. Int J. Psychophysiol., 2012, 84: 246-253

[105] Prasad S et al. Preliminary evidence that acute stress moderates basal testosterone’s association with retaliatory behavior. Horm. Behav., 2017, 92: 128-140

[106] Bingaman EW et al. Androgen inhibits the increases in hypothalamic corticotropin-releasing hormone (CRH) and CRH-immunoreactivity following gonadectomy. Neuroendocrinology, 1994, 59: 228-234

[107] Handa RJ et al. Androgen regulation of adrenocorticotropin and corticosterone secretion in the male rat following novelty and foot shock stressors. Physiol. Behav., 1994, 55: 117-124

[108] Hunt KE et al. Multi-year patterns in testosterone, cortisol and corticosterone in baleen from adult males of three whale species. Conserv. Physiol., 2018, 6: coy049

[109] Karsenty G, Olson EN. Bone and muscle endocrine functions: unexpected paradigms of Inter-organ communication. Cell, 2016, 164: 1248-1256

[110] Oury F et al. Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. J. Clin. Investig., 2013, 123: 2421-2433

[111] Lee NK et al. Endocrine regulation of energy metabolism by the skeleton. Cell, 2007, 130: 456-469

[112] Li L et al. Acute psychological stress results in the rapid development of insulin resistance. J. Endocrinol., 2013, 217: 175-184

[113] Yan YX et al. Investigation of the relationship between chronic stress and insulin resistance in a chinese population. J. Epidemiol., 2016, 26: 355-360

[114] Marik, P. E. Endocrinology of the stress response during critical illness. Critical Care Nephrology 3rd edn, 446–454 (Elsevier, 2019).

[115] Whirledge S, Cidlowski JA. Glucocorticoids and reproduction: traffic control on the road to reproduction. Trends Endocrinol. Metab., 2017, 28: 399-415

[116] Du J et al. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK. Endocrine, 2016, 53: 701-709

[117] Ferron M et al. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone, 2012, 50: 568-575

[118] Coskun G et al. Effects of osteocalcin on synthesis of testosterone and INSL3 during adult leydig cell differentiation. Int. J. Endocrinol., 2019, 2019: 1041760

[119] Clemens TL et al. Analysis of osteocalcin expression in transgenic mice reveals a species difference in vitamin D regulation of mouse and human osteocalcin genes. J. Bone Min. Res., 1997, 12: 1570-1576

[120] Jørgensen S et al. Genetic variations in the human G protein-coupled receptor class C, group 6, member A (GPRC6A) control cell surface expression and function. J. Biol. Chem., 2017, 292: 1524-1534

[121] Pi M et al. Humanized GPRC6A. Sci. Rep., 2020, 10

[122] De Toni L et al. Polymorphism rs2274911 of GPRC6A as a novel risk factor for testis failure. J. Clin. Endocrinol. Metab., 2016, 101: 953-961

[123] White R et al. Structural organization and expression of the mouse estrogen receptor. Mol. Endocrinol., 1987, 1: 735-744

[124] Cuitavi J, Hipólito L, Canals M. The life cycle of the Mu-Opioid receptor. Trends Biochem. Sci., 2021, 46: 315-328

[125] Verstockt B et al. Genome-wide association studies in Crohn’s disease: past, present and future. Clin. Transl. Immunol., 2018, 7: e1001

[126] Zheng J et al. Mendelian randomization analysis reveals a causal influence of circulating sclerostin levels on bone mineral density and fractures. J. Bone Min. Res., 2019, 34: 1824-1836

[127] Sebastian A, Loots GG. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models. Metabolism, 2018, 80: 38-47

[128] Shoback, D. et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J. Clin. Endocrinol. Metab. 105, 587–594 (2020).

[129] Diegel CR et al. An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genet., 2020, 16: e1008361

[130] Moriishi T et al. Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass. PLoS Genet., 2020, 16: e1008586

[131] Adikusuma F et al. Large deletions induced by Cas9 cleavage. Nature, 2018, 560: E8-E9

[132] Xia M. Osteocalcin and non-alcoholic fatty liver disease: lessons from two population-based cohorts and animal models. J. Bone Miner. Res., 2021, 36: 712-728

[133] Huang L et al. Osteocalcin improves metabolic profiles, body composition and arterial stiffening in an induced diabetic rat model. Exp. Clin. Endocrinol. Diabetes, 2017, 125: 234-240

[134] Jørgensen CV et al. Metabolic and skeletal homeostasis are maintained in full locus GPRC6A knockout mice. Sci. Rep., 2019, 9

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation)(RA1923/12-1)

Mildred Scheel Nachwuchszentrum German Academic Scholarship Foundation